Unichem Labs osteoarthritis drug Celecoxib gets USFDA okay
The capsules are generic versions of GD Searle LLC's Celebrex capsules in the same strengths, it added.
New Delhi: Drug firm, Unichem Laboratories on Wednesday said it has received approval from the US health regulator to market its generic Celecoxib capsules used for the treatment of osteoarthritis, rheumatoid arthritis, and acute pain.
The company has received abbreviated new drug application (ANDA) approval for its Celecoxib capsules in the strengths of 50 mg, 100 mg, 200 mg, and 400 mg from the United StatesFood and Drug Administration (USFDA), Unichem said in a filing to BSE.
The capsules are generic versions of GD Searle LLC's Celebrex capsules in the same strengths, it added.
The product will be commercialized from the company's Goa plant, the filing said.
"Celecoxib capsules are indicated for the treatment of osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain and primary dysmenorrhea," it added.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.